Drug Type Biosimilar, Monoclonal antibody |
Synonyms Denosumab Biosimilar (Alvotech hf), デノスマブ(遺伝子組換え)[デノスマブ後続1](JAN)(富士製薬工業株式会社), 地舒单抗生物类似药(Alvotech hf) + [9] |
Target |
Action inhibitors |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (19 Sep 2025), |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D03684 | Denosumab biosimilar (Alvotech) |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypogonadal osteoporosis | United Kingdom | 05 Dec 2025 | |
| Bone Cancer | European Union | 25 Nov 2025 | |
| Bone Cancer | Iceland | 25 Nov 2025 | |
| Bone Cancer | Liechtenstein | 25 Nov 2025 | |
| Bone Cancer | Norway | 25 Nov 2025 | |
| Bone Diseases, Metabolic | European Union | 25 Nov 2025 | |
| Bone Diseases, Metabolic | Iceland | 25 Nov 2025 | |
| Bone Diseases, Metabolic | Liechtenstein | 25 Nov 2025 | |
| Bone Diseases, Metabolic | Norway | 25 Nov 2025 | |
| Osteoporosis | European Union | 25 Nov 2025 | |
| Osteoporosis | Iceland | 25 Nov 2025 | |
| Osteoporosis | Liechtenstein | 25 Nov 2025 | |
| Osteoporosis | Norway | 25 Nov 2025 | |
| Fractures, Spontaneous | European Union | 17 Nov 2025 | |
| Fractures, Spontaneous | European Union | 17 Nov 2025 | |
| Fractures, Spontaneous | Iceland | 17 Nov 2025 | |
| Fractures, Spontaneous | Iceland | 17 Nov 2025 | |
| Fractures, Spontaneous | Liechtenstein | 17 Nov 2025 | |
| Fractures, Spontaneous | Liechtenstein | 17 Nov 2025 | |
| Fractures, Spontaneous | Norway | 17 Nov 2025 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporotic Fractures | NDA/BLA | European Union | 18 Sep 2025 | |
| Osteoporotic Fractures | NDA/BLA | European Union | 18 Sep 2025 | |
| Immune System Diseases | Preclinical | Iceland | - | |
| Neoplasms | Preclinical | Iceland | - |
Phase 1 | - | 208 | (Experimental Arm AVT03 120mg) | rvnjgqaecq(nitntyrngu) = nxnwozyate yuzwdfrrws (ofxvlnpkgh, 34) View more | - | 15 May 2025 | |
(Active Comparator Xgeva 120mg) | rvnjgqaecq(nitntyrngu) = rvswgdhbfp yuzwdfrrws (ofxvlnpkgh, 32) View more | ||||||
Phase 1 | - | 208 | mctjjtaknh(xvwzpfkwnb) = ymsnkxenzv ebwficgyxo (csrawgkqas ) | Positive | 10 Apr 2025 | ||
Reference Product | mctjjtaknh(xvwzpfkwnb) = ekqkjbasph ebwficgyxo (csrawgkqas ) | ||||||
Phase 1 | - | 206 | - | Positive | 10 Apr 2025 | ||
Reference Product (60 mg/mL) | |||||||
Phase 3 | 532 | xoehrjmcwo(qqxfhcluav): Geometric mean ratio = 1.0 (95.0% CI, 0.97 - 1.03) | Positive | 10 Apr 2025 | |||
Phase 1 | 208 | hkfkfgspfp(wxmsohumwq) = we have now obtained positive topline results from two PK studies, that show equivalent PK, safety, and tolerability of AVT03 compared to Prolia and Xgeva, respectively. curorlqtct (vnjpgdwens ) Met | Similar | 02 Jul 2024 | |||
Phase 1 | - | - | owoddousrn(abribwndnp) = met its primary endpoints rdatclrpcp (fbzkwmzjgc ) Met View more | Positive | 29 Jan 2024 |






